Flagship Pioneering’s Post

Today, we announced a new collaboration under the Flagship Pioneering-Pfizer partnership to leverage our AND™ Platform to identify programmable biologics for the treatment of obesity. Our AND-Body™ Therapeutics are designed to target disease sites precisely, to drive better activity without affecting healthy tissues or cells. This collaboration is just one of many potential applications of our platform in obesity and beyond. Read more about our first partnership and learn how we’re unlocking novel approaches to targets in disease areas of significant unmet need: https://bit.ly/3YWeGni #Biotech #Innovation #DrugDevelopment #FlagshipFounded